Fibromyalgia & musculoskeletal pain
Composite Autonomic Symptom Score 31 (COMPASS-31) for the assessment of symptoms of autonomic dysfunction in fibromyalgia
Authors' conclusion
This study highlights the high prevalence of autonomic dysfunction in FM and supports the utility of COMPASS-31 as a reliable tool for assessing autonomic symptoms in FM patients.
Study context
- Population
- Women with FM and matched healthy controls
- Participants
- 77 vs 77
- Exposure
- Women with FM vs matched healthy controls
- FMn = 77
- Controlsn = 77reference
- Outcome
- Autonomic dysfunction assessed by COMPASS-31
Methodological detailsmatched healthy controls
- Matched healthy controls
Main finding
As reported in the abstract
Autonomic dysfunction (COMPASS-31)
Observational data: associations, not effects.
Further findings
| Outcome | FM | Controls | P value |
|---|---|---|---|
| COMPASS-31 score | mean 47.03 (SD 17.27) | 21.55 (SD 11.48) | P < 0.00001 |
Internal consistency of COMPASS-31
- Cronbach's α
- 0.74
- Good
COMPASS-31 cut-off 38.28 distinguishing FM from healthy controls
- Sensitivity
- 71.43%
- Specificity
- 91.86%
- LR+
- 8.78
Correlation of COMPASS-31 with FM severity measures
- Fibromyalgia Impact Questionnaire (FIQR) rho=0.47
- P < 0.0001
- Polysymptomatic Distress Scale (PDS) rho=0.36
- P < 0.0001
- FASmod rho=0.32
- P = 0.004
- PainDetect Questionnaire (PDQ) rho=0.56
- P < 0.0001
- Positive correlations
FIQR disease severity categories and autonomic dysfunction symptoms
- Kruskal-Wallis test 18.77
- P = 0.00086
- Significantly associated
Original publication
Composite Autonomic Symptom Score 31 (COMPASS-31) for the assessment of symptoms of autonomic dysfunction in fibromyalgia. Clin Exp Rheumatol. Published 14 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →